Galenica : lays foundation for two listed, independent companies

_Following the successful systematic implementation of its transformation strategy since 1995, the Galenica Group is now preparing for a new phase. Accordingly, its operational management structure is being adapted.

_In future, the Group will be headed by two CEOs: one CEO for Vifor Pharma (former Pharma Division) and one CEO for Galenica Santé (former Santé Division). Both CEOs will report directly to the Executive Chairman. The role of CEO Galenica Group is being abolished.

_The new management structure will enable the different Pharma and Santé business models to develop in an even more focused way, taking into account their individual growth dynamics. With this move, the Board of Directors of the Galenica Group is creating the best possible conditions for both the Vifor Pharma and Galenica Santé units to prepare to become listed, independent companies when the time is right.

_The Board of Directors of the Galenica Group has appointed Søren Tulstrup as CEO of the Vifor Pharma Division and Jörg Kneubühler as CEO of the Galenica Santé Division. Jörg Kneubühler will also continue to be CFO of the Galenica Group. The new structure will enter into effect immediately.

_David Ebsworth, who has been CEO of Vifor Pharma since 2009 and was appointed CEO Galenica Group in 2011, has decided to step down from his operational duties and to take well-earned retirement from 31 August 2015. He will continue to support the Galenica Group in a Special Projects role given his knowledge and excellent pharma expertise. David Ebsworth has made a considerable contribution to the success of the Galenica Group through his tireless commitment over the past five years.

Read more

_Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).